It's been a rough couple of sessions for Raptor Pharmaceuticals (RPTP) as the shares are off some 9.5% since last Thursday (although still up ~116% YTD).
The company could have done without comments out of Favus, where analysts have reportedly called Procysbi "a situation akin to Acthar Gel, with one major difference: The availability of a substantially cheaper version (Cystagon) of the exact same drug [where the] only difference is dosing frequency."
Also mentioned is UnitedHealth's supposed move to put Procysbi on 2014's excluded drug list.
Summing up, Favus has a question for RPTP investors: "At what price would QCOR trade if a generic version of Acthar Gel was available at a 96% discount?" The firm calls the similarities between RPTP and QCOR "striking."